MRKR is trading at $1.39 (+5.70%) in pre-market, likely driven by broad risk-on sentiment as U.S. index futures trend higher and biotech names benefit from a stronger open.
- There are no confirmed earnings releases, FDA updates, or major company-specific headlines from Marker Therapeutics to account for the move.
- The price action follows a quiet close on June 26, with the stock appearing to move in tandem with the wider sector's positive momentum.